Pfizer Begins Human Trials of New Pill to Treat Coronavirus

Subscribe to The Global Herald in Google News

Bloomberg Quicktake: Now published this video item, entitled “Pfizer Begins Human Trials of New Pill to Treat Coronavirus” – below is their description.

Pfizer Inc. said it has begun human safety testing of a new pill to treat the coronavirus that could be used at the first sign of illness.

If it succeeds in trials, the pill could be prescribed early in an infection to block viral replication before patients get very sick. The drug binds to an enzyme called a protease to keep the virus from replicating. Protease-inhibiting medicines have been successful in treating other types of viruses, include HIV and Hepatitis C.

“Given the way that SARS-CoV-2 is mutating and the continued global impact of Covid-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic,” said Mikael Dolsten, Pfizer’s Chief Scientific Officer, in a statement.

In an interview, Dolsten said no unexpected problems had been seen in the study so far and that it could generate results within weeks.

The new protease inhibitor is the second such medicine Pfizer has brought into human trials to treat Covid-19. Pfizer is testing another given intravenously to hospitalized virus patients.

Shares of Pfizer were down 1.3% to $35.55 at 12:36 p.m. in New York. Over the past year, the stock has climbed 32%.

Easy-to-use treatments are lacking for early-stage Covid-19 patients. While antibody therapies from Eli Lilly & Co. and Regeneron Pharmaceuticals Inc. are authorized in the U.S. for Covid patients who haven’t yet been hospitalized but are at high risk of developing severe symptoms, they must be infused in the hospital or at a doctor’s office.

That has created logistical challenges that have limited their use. Other therapies are intended for sicker people: Gilead Sciences Inc.’s antiviral drug remdesivir must be infused over several days and is approved only for hospitalized patients.

Among major drugmakers, Merck & Co. has one of the few coronavirus pills that is far along in human testing. Its experimental antiviral drug molnupiravir works by a different mechanism than the Pfizer drug and is in late-stage human trials. Merck is developing its drug in collaboration with Ridgeback Biotherapeutics LP.

Combined Trial

If everything continues to go well, Pfizer could begin a much larger combined phase 2-phase 3 trial early in the second quarter, Dolsten said, potentially allowing it to apply for emergency-use authorization from the Food and Drug Administration by the end of this year, depending on how the pandemic evolves.

The drug is likely to be given twice a day for about five days, he said.

“This is really a potential game changer,” Dolsten said.

While initial efficacy testing will focus on people with early infections, Pfizer also plans to explore whether the drug works to protect healthy people who have been exposed to the coronavirus, such as family members or roommates who live with someone who got sick.

Dolsten said Pfizer’s oral protease inhibitor, code-named PF-07321332, had a number of potential advantages. In lab tests, it worked against many coronaviruses, including the original SARS virus and MERS. Additionally, the coronavirus protease doesn’t mutate much, which means the therapy is likely to work equally well against numerous variant strains, he said.

In theory, the protease inhibitor could also be combined with other antiviral drugs, such as the one Merck is developing, Dolsten said.

Pfizer said it plans to share more data on the compound at the American Chemical Society meeting on April 6.

Bloomberg Quicktake: Now YouTube Channel

Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.


Subscribe to The Global Herald in Google News

Similar Content

About This Source - Bloomberg QuickTake: Now

Bloomberg L.P. is a privately held financial, software, data, and media company headquartered in Midtown Manhattan, New York City.

It was founded by Michael Bloomberg in 1981, with the help of Thomas Secunda, Duncan MacMillan, Charles Zegar, and a 12% ownership investment by Merrill Lynch.

Recent from Bloomberg QuickTake: Now:

  • U.K. Prime Minister Boris Johnson Faces Calls to Resign Over ‘Partygate’
  • Scientists Race to Save Submerged Roman City From Rock-Eating Bacteria
  • Boosters Effectively Fend Off Delta, Omicron Variants in Studies
  • In This Story: COVID-19

    Covid-19 is the official WHO name given to the novel coronavirus which broke out in late 2019 and began to spread in the early months of 2020.

    Symptoms of coronavirus

    The main symptoms of coronavirus are:

    • a persistent new cough (non productive, dry)
    • a high temperature (e.g. head feels warm to the touch)
    • shortness of breath (if this is abnormal for the individual, or increased)

    Latest News about Covid-19

    Below are stories from around the globe related to the 2020 outbreak of novel Coronavirus – since the WHO gave the Covid-19 naming. Most recent items are posted nearest the top.

    5 Recent Items: COVID-19

  • CDC Data Shows Covid Booster Shots Highly Protective
  • Boosters Effectively Fend Off Delta, Omicron Variants in Studies
  • Can antibody testing reveal which variant you’ve had?
  • Lessons learned since 1st COVID case confirmed in US 2 years ago
  • Covid lockdowns ‘have proven to be an utter failure’: Head of Medicine at Stanford Medical School
  • In This Story: HIV

    The human immunodeficiency viruses (HIV) are two species of Lentivirus (a subgroup of retrovirus) that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.

    Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. In most cases, HIV is a sexually transmitted infection and occurs by contact with or transfer of blood, pre-ejaculate, semen, and vaginal fluids. Research has shown (for both same-sex and opposite-sex couples) that HIV is untransmittable through condomless sexual intercourse if the HIV-positive partner has a consistently undetectable viral load.

    Non-sexual transmission can occur from an infected mother to her infant during pregnancy, during childbirth by exposure to her blood or vaginal fluid, and through breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.

    For help & assistance

    5 Recent Items: HIV

  • Fauci’s NIH caught funding ‘cruel’ experiments on monkeys: PETA
  • Omicron-Update: Soaring COVID-19 infections around the world | DW News
  • Desmond Tutu: A strong voice in the fight against HIV-AIDS
  • Blanket Booster Programs May Prolong Covid Pandemic, WHO Says
  • Scientists research link between Covid variants and untreated HIV – BBC News
  • In This Story: Merck

    Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. Merck is incorporated in New Jersey.

    2 Recent Items: Merck

  • Final Trades: Wynn, Goldman Sachs, Merck & more
  • COVID-19: Canadian officials provide update following Pfizer antiviral pill approval | LIVE
  • In This Story: Pfizer

    Pfizer Inc. (NYSE: PFE) is an American multinational pharmaceutical corporation headquartered in New York City. In 2012, it was one of the world’s largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

    5 Recent Items: Pfizer

  • Boosters Effectively Fend Off Delta, Omicron Variants in Studies
  • Israel Reports Record Number of New Daily Covid Infections
  • Early Omicron Breakthroughs Show MRNA Vaccines’ Weakness
  • New Brunswick issues call for volunteers to help with COVID-19 response
  • Israel Trial Suggests 4th Vaccine Dose Didn’t Block Omicron
  • Leave a Comment

    We don't require your email address, or your name, for anyone to leave a comment. If you do add an email address, you may be notified if there are replies to your comment - we won't use it for any other purpose. Please make respectful comments, which add value, and avoid personal attacks on others. Links are not allowed in comments - 99% of spam comments, attempt to post links. Please describe where people may find additional information - for example "visit the UN website" or "search Google for..." rather than posting a link. Comments failing to adhere to these guidelines will not be published.

    Posting....